Tier 3 — preclinical

Quercetin as an Agent for Protecting the Bone: A Review of the Current Evidence

Sok Kuan Wong, Kok-Yong Chin, Soelaiman Ima-Nirwana
International journal of molecular sciences 2020 21(17):6448

Bibliography

PubMed
PMID 32899435
PubMed Central
PMC7503351
DOI
10.3390/ijms21176448
Funding
Indexed grant support: GGPM-2020-012 — Universiti Kebangsaan Malaysia. The indexed list may not contain the complete funding declaration.
Competing interests
Reported disclosure: The authors declare no conflict of interest.

Study snapshot

DesignNarrative review of predominantly preclinical bone research
ModelNarrative or mixed evidence review
SampleAnimal and laboratory studies; no new human trial cohort
InterventionQuercetin across bone-remodeling models
DurationLiterature available at publication
EndpointsBone or cartilage measures

What the study showed, in plain terms

Published in 2020, this source examined bone and joint health. Design: Narrative review of predominantly preclinical bone research. Sample/model: Animal and laboratory studies; no new human trial cohort. The exposure or intervention was Quercetin across bone-remodeling models. Follow-up or treatment period: Literature available at publication.

Most reviewed models suggested bone-protective effects, although some results were negative or pathway-dependent.

Competing molecular actions and preclinical models do not establish reduced fractures or improved bone density in humans.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Inflammation: CRP, Pain and Human Trials. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Most reviewed models suggested bone-protective effects, although some results were negative or pathway-dependent.
  • The recorded outcome domains were Bone or cartilage measures.
  • The result applies to the tested exposure: Quercetin across bone-remodeling models; Literature available at publication.

What this study can and cannot tell us

  • Competing molecular actions and preclinical models do not establish reduced fractures or improved bone density in humans.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology